Clinical Scorecard: Comparative Efficacy of Selpercatinib and Multi-Kinase Inhibitors in Advanced Medullary Thyroid Cancer: A Network Meta-Analysis of RET Inhibitors

At a Glance

Key Highlights

• Selpercatinib shows the most significant progression-free survival (PFS) benefit compared to other agents.
• Selpercatinib ranks first for objective response rate (ORR).
• Selpercatinib has a more favorable safety profile compared to multi-kinase inhibitors.
• Anlotinib exhibited the highest toxicity among the agents studied.
• Clinical decisions should be individualized due to heterogeneity in patient populations.

Guideline-Based Recommendations

Diagnosis

• Histopathological confirmation of advanced MTC is required.

Management

• Selpercatinib is recommended as a first-line option for advanced MTC.

Monitoring & Follow-up

• Monitor for ≥Grade 3 adverse events, particularly hepatotoxicity.

Risks

• Consider off-target toxicities associated with multi-kinase inhibitors, such as hypertension and diarrhea.

Patient & Prescribing Data

Patients with advanced medullary thyroid cancer, including those with mixed RET mutation status.

Selpercatinib offers enhanced efficacy and improved safety compared to traditional multi-kinase inhibitors.

Clinical Best Practices

• Utilize network meta-analysis data to inform treatment selection.
• Assess individual patient characteristics and RET mutation status when prescribing.

Related Resources & Content

• Systematic review registration